Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Soleno Therapeutics (SLNO) Accumulated Depreciation & Amortization (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $31000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 66.67% to $31000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $31000.0, a 66.67% decrease, with the full-year FY2019 number at $31000.0, down 66.67% from a year prior.
  • Accumulated Depreciation & Amortization was $31000.0 for Q4 2019 at Soleno Therapeutics, down from $93000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $211595.0 in Q4 2015 to a low of $31000.0 in Q4 2019.
  • A 5-year average of $89609.0 and a median of $74000.0 in 2017 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 81.83% in 2016, then soared 92.46% in 2017.
  • Soleno Therapeutics' Accumulated Depreciation & Amortization stood at $211595.0 in 2015, then plummeted by 81.83% to $38450.0 in 2016, then skyrocketed by 92.46% to $74000.0 in 2017, then increased by 25.68% to $93000.0 in 2018, then plummeted by 66.67% to $31000.0 in 2019.
  • Per Business Quant, the three most recent readings for SLNO's Accumulated Depreciation & Amortization are $31000.0 (Q4 2019), $93000.0 (Q4 2018), and $74000.0 (Q4 2017).